VIA
ZBIO icon

Virtus Investment Advisers’s Zenas BioPharma ZBIO Stock Holding History

Virtus Investment Advisers’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419K Buy
16,525
+9,808
+146% +$195K 0.1% 253
2026
Q1 		$131K Buy
6,717
+163
+2% +$3.66K 0.04% 445
2025
Q4 		$238K Buy
+6,554
New +$216K 0.06% 349

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Virtus Investment Advisers's ZBIO Position: Q2 2026 in Review

Virtus Investment Advisers increased its Zenas BioPharma (ZBIO) stake by 146% in Q2 2026, buying an estimated $195K and bringing the position to 16,525 shares worth $419K. The position accounts for 0.1% of the portfolio, ranked #253.

Virtus Investment Advisers first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Virtus Investment Advisers held 16,525 shares of Zenas BioPharma worth $419K as of Q2 2026.
  • Virtus Investment Advisers bought 9,808 Zenas BioPharma shares in Q2 2026, an estimated $195K.
  • Zenas BioPharma made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #253 holding.
  • Virtus Investment Advisers first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.